欧美AV

The cell and gene therapy sector is accelerating faster than the systems designed to pay for it. With 39 FDA approved CGTs and more than 80 expected by 2032, the widening gap between scientific progress and pricing, policy, and reimbursement frameworks is threatening real world patient access. At the same time, the last year has brought major changes, from the Cell and Gene Therapy Access Model and outcomes based agreements to rising concerns about coverage and the policy changes still to come.

Returning to Washington DC, the 3rd Cell and Gene Therapy Pricing and Reimbursement Summit is the only meeting built specifically for cell and gene therapy biopharma, commercial and government payers, policymakers, and healthcare providers to confront these challenges head on. Through exclusive case studies from newly commercialized companies, deep dives into the latest policy shifts, and practical frameworks for value communication, you鈥檒l gain the insights needed to navigate the current commercialization landscape and be part of the conversation discussing what policy changes will be needed next.

Join the stakeholders defining the future of cell and gene therapy affordability, and leave with the strategies to secure coverage, expand treatment capacity, and unlock patient access in 2026 and beyond.